Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gemina Laboratories Ltd. GLABF


Primary Symbol: C.GLAB

Healthcare Diagnostics & Research
Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the... see more

Recent & Breaking News (CSE:GLAB)

Gemina Labs Enters into Licence and Manufacturing Agreements

Accesswire October 6, 2022

Gemina Labs Presents at the H.C. Wainwright Global Investment Conference

Accesswire September 12, 2022

Gemina Labs Appoints Diagnostic Executive Brian Firth as Chief Executive Officer

Accesswire September 6, 2022

Gemina Labs Announces Closing Of Concurrent Private Placement

Accesswire July 11, 2022

Gemina Announces Closing Of Prospectus Supplement Offering And Update To Concurrent Non-brokered Private Placement

Accesswire June 30, 2022

Gemina Announces Filing of Prospectus Supplement

Accesswire June 24, 2022

Gemina Announces Proposed Financing Up to $5 Million

Accesswire June 21, 2022

Gemina Labs Appoints Point-of-Care Diagnostic Executive Brian Firth as Advisor

Accesswire June 8, 2022

Gemina Labs Announces CE Mark for its First Product - The Best in Class Legio-X COVID Rapid Antigen Test

Accesswire May 17, 2022

Gemina Labs Completes Successful Human Clinical Performance Evaluation on its Legio X COVID-19 Rapid Antigen Test

Accesswire May 5, 2022

Gemina Labs Nears Completion of Phase 2 Human Patient Testing for Initial Diagnostic Test

Accesswire April 28, 2022

Gemina Labs Provides Technical Development Update for Initial Diagnostic Test and Reports Filing of New IP

Accesswire March 31, 2022

Gemina Labs Establishes UK Subsidiary And Appoints David Browning As Head Of Productization

Accesswire February 23, 2022

Gemina Labs Strategic Update: From Product to Platform, Gemina Provides a Technology Roadmap

Accesswire February 15, 2022

Gemina Labs Announces Completion of Significant Development Step for its SARS-CoV-2 Rapid Test

Accesswire February 3, 2022

Gemina Labs Announces Appointment Of Senior Scientific Adviser

Accesswire November 18, 2021

Gemina Labs Announces Closing of Oversubscribed Private Placement

Accesswire October 25, 2021

Gemina Labs Announces Private Placement

Accesswire October 20, 2021

Gemina Labs Receives Positive Initial Manufacturing Results for SARS-CoV-2 Diagnostic Test

Accesswire September 20, 2021

Gemina Labs Provides Research and Development and Corporate Update

Accesswire September 13, 2021